API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Vitrakvi® (larotrectinib) is that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, which is investigated for the treatment of infantile fibrosarcoma.
Lead Product(s): Larotrectinib
Therapeutic Area: Oncology Product Name: Vitrakvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Vitrakvi (Larotrectinib), is a first-in-class, highly selective TRK inhibitor exclusively designed to treat solid tumors that have an NTRK gene fusion, also called TRK fusion solid tumors. It has shown powerful efficacy with high and durable responses and high safety profile.
Lead Product(s): Larotrectinib
Therapeutic Area: Oncology Product Name: Vitrakvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
In an expanded data set with a longer follow-up (cut-off July 15, 2019) of 175 patients (116 adult and 59 pediatric) with non-primary central nervous system (CNS) TRK fusion cancer, Vitrakvi demonstrated a durable, investigator-assessed overall response rate (ORR) of 78%.
Lead Product(s): Larotrectinib
Therapeutic Area: Oncology Product Name: Vitrakvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020